A Phase 1 interventional study of AMG 890 and Placebo in Cardiovascular Disease, sponsored by Amgen. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 79 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Ascending Dose Cohorts
Drug: Placebo
Single Ascending Dose Cohorts
Drug: AMG 890
Ascending Single Doses of AMG 890
Calculated volume to match experimental drug.
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
An adverse event was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as any event with onset after the administration of the first dose of investigational product and up to and including the end of treatment date, or end of trial for participants who discontinued the trial during the treatment period. Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes were included as TEAEs.
Time frame: From first dose of trial until the end of trial; median (min, max) duration was 8.54 (0.23, 23.92) months
Maximum Observed Concentration (Cmax) of Olpasiran
Blood samples were collected for measurement of serum concentrations of Olpasiran.
Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Time to Reach Cmax (Tmax) of Olpasiran
Blood samples were collected for measurement of serum concentrations of Olpasiran.
Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran
Blood samples were collected for measurement of serum concentrations of Olpasiran.
Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Change From Baseline in Plasma Lp(a) Levels
Change from baseline for plasma Lp(a) by cohort and at scheduled time points were presented.
Time frame: Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365
Percent Change From Baseline in Plasma Lp(a) Levels
Percent change from baseline for plasma Lp(a) by cohort and at scheduled time points during the treatment period were presented.
Time frame: Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365
Participants were enrolled at 8 research centers in the United States (US) and Australia between July 2018 and April 2023.
| Milestone | Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 20 | 6 | 6 | 6 | 6 | 6 | 9 | 9 | 5 | 6 |
| Participants who received placebo in cohorts 1-5 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants who received placebo in cohorts 6-9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 17 | 6 | 4 | 6 | 2 | 3 | 8 | 6 | 5 | 5 |
| Not completed | 3 | 0 | 2 | 0 | 4 | 3 | 1 | 3 | 0 | 1 |
| Withdrew: Withdrawal of consent from study | 2 | 0 | 0 | 0 | 4 | 3 | 0 | 0 | 0 | 1 |
| Withdrew: Decision by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as any event with onset after the administration of the first dose of investigational product and up to and including the end of treatment date, or end of trial for participants who discontinued the trial during the treatment period. Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes were included as TEAEs.
| Participants | Cohorts 1-5: Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohorts 6-9: Placebo | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | 5 | 3 | 3 | 5 | 1 | 0 | 7 | 6 | 3 | 4 | 4 |
Blood samples were collected for measurement of serum concentrations of Olpasiran.
| ng/mL | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Olpasiran | 11.7 ± 2.36 | 36.1 ± 19.7 | 74.9 ± 25 | 252 ± 153 | 421 ± 223 | 17.4 ± 7.48 | 111 ± 56.3 | 1390 ± 947 | 2620 ± 888 |
Blood samples were collected for measurement of serum concentrations of Olpasiran.
| hours | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of Olpasiran | 3.0 (1.0 to 9.0) | 3.0 (3.0 to 6.0) | 7.5 (1.0 to 9.0) | 4.5 (0.17 to 9.0) | 6.0 (1.0 to 12) | 3.0 (1.0 to 9.0) | 6.0 (3.0 to 24) | 3.0 (1.0 to 23) | 4.5 (2.1 to 6.2) |
Blood samples were collected for measurement of serum concentrations of Olpasiran.
| hour*ng/mL | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran | 116 ± 39.8 | 352 ± 141 | 1020 ± 329 | 2830 ± 730 | 7800 ± 1670 | 240 ± 96.3 | 2060 ± 642 | 29600 ± 23500 | 44800 ± 16400 |
Change from baseline for plasma Lp(a) by cohort and at scheduled time points were presented.
| nmol/L | Cohorts 1-5: Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohorts 6-9: Placebo | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from baseline to Day 2 | 9.740 ± 11.415 | -17.820 ± 16.662 | -1.417 ± 9.409 | 9.412 ± 13.240 | 1.937 ± 2.589 | -6.438 ± 14.001 | -54.862 ± 91.381 | -4.886 ± 24.160 | -15.119 ± 79.070 | -88.586 ± 105.991 | -86.940 ± 134.234 |
| Change from baseline to Day 4 | 11.450 ± 13.155 | -13.020 ± 17.499 | -8.317 ± 13.271 | 3.862 ± 12.344 | -23.080 ± 12.246 | -13.455 ± 11.489 | -55.527 ± 100.807 | -33.358 ± 21.037 | -49.659 ± 70.520 | -116.986 ± 71.397 | -146.718 ± 165.278 |
| Change from baseline to Day 7 | 0.410 ± 12.785 | -24.170 ± 21.798 | -35.283 ± 13.307 | -32.272 ± 7.480 | -45.863 ± 8.095 | -69.188 ± 35.265 | -32.389 ± 99.479 | -77.707 ± 47.138 | -102.508 ± 75.135 | -203.215 ± 112.549 | -204.990 ± 159.912 |
| Change from baseline to Day 15 | -2.530 ± 16.293 | -59.137 ± 28.794 | -76.094 ± 22.915 | -63.772 ± 10.074 | -96.580 ± 11.663 | -98.938 ± 30.749 | -35.367 ± 54.976 | -138.618 ± 38.215 | -208.459 ± 81.219 | -277.226 ± 135.590 | -294.890 ± 176.007 |
| Change from baseline to Day 18 | -6.940 ± 15.926 | -71.070 ± 26.156 | -85.594 ± 24.516 | -76.222 ± 13.730 | -108.463 ± 16.162 | -122.205 ± 30.732 | — | — | — | — | — |
| Change from baseline to Day 22 | -3.450 ± 14.989 | -77.853 ± 25.502 | -93.714 ± 22.458 | -79.388 ± 15.566 | -117.813 ± 19.714 | -126.788 ± 32.793 | — | — | — | — | — |
| Change from baseline to Day 29 | -1.350 ± 14.355 | -82.037 ± 26.703 | -104.894 ± 26.885 | -86.038 ± 18.938 | -124.713 ± 23.769 | -134.605 ± 36.395 | -46.909 ± 72.951 | -188.740 ± 37.700 | -270.641 ± 95.753 | -330.115 ± 171.096 | -366.214 ± 199.738 |
| Change from baseline to Day 43 | -7.720 ± 14.629 | -89.787 ± 25.866 | -108.734 ± 28.948 | -90.072 ± 20.412 | -129.230 ± 25.491 | -140.572 ± 36.947 | -33.244 ± 64.989 | -197.673 ± 36.630 | -282.841 ± 95.711 | -257.585 ± 30.464 | -351.707 ± 193.404 |
| Change from baseline to Day 57 | 2.620 ± 11.739 | -87.220 ± 29.478 | -106.834 ± 27.834 | -89.955 ± 20.435 | -129.513 ± 26.035 | -140.922 ± 36.663 | -27.973 ± 104.520 | -200.251 ± 40.105 | -288.874 ± 100.724 | -331.386 ± 166.191 | -353.207 ± 193.827 |
| Change from baseline to Day 71 | -0.392 ± 14.313 | -83.970 ± 24.076 | -97.518 ± 24.356 | -88.805 ± 22.440 | -128.797 ± 26.709 | -140.572 ± 37.216 | — | — | — | — | — |
| Change from baseline to Day 85 | 2.497 ± 12.877 | -73.953 ± 23.337 | -96.318 ± 23.377 | -85.072 ± 21.123 | -127.980 ± 27.181 | -139.255 ± 36.247 | -35.246 ± 98.490 | -185.407 ± 42.933 | -275.519 ± 95.029 | -330.806 ± 167.145 | -352.923 ± 194.316 |
| Change from baseline to Day 113 | 4.697 ± 6.955 | -63.103 ± 28.733 | -89.168 ± 24.019 | -82.338 ± 24.960 | -123.147 ± 26.883 | -137.038 ± 36.491 | -26.599 ± 83.420 | -162.829 ± 50.183 | -253.641 ± 93.836 | -325.526 ± 168.995 | -276.696 ± 75.437 |
| Change from baseline to Day 155 | -13.990 ± 14.136 | — | — | -63.566 ± 26.356 | -123.076 ± 29.946 | -144.877 ± 24.157 | -32.339 ± 101.724 | -132.696 ± 52.950 | -195.725 ± 50.429 | -304.846 ± 173.370 | -368.258 ± 212.962 |
| Change from baseline to Day 183 | -20.770 ± 10.748 | — | — | — | -109.435 ± 31.304 | -140.143 ± 25.143 | -32.749 ± 77.047 | -109.740 ± 41.868 | -176.781 ± 51.330 | -291.966 ± 167.126 | -338.990 ± 202.609 |
| Change from baseline to Day 225 | -3.902 ± 18.584 | — | — | -64.100 ± NA | -104.285 ± 36.607 | -111.892 ± 27.648 | -15.849 ± 70.823 | -85.218 ± 39.572 | -165.297 ± 89.184 | -257.226 ± 167.618 | -320.223 ± 207.672 |
| Change from baseline to Day 253 | — | — | — | — | — | — | -101.640 ± 58.930 | — | — | -276.490 ± 179.094 | -318.725 ± 259.063 |
| Change from baseline to Day 281 | — | — | — | — | — | — | -96.107 ± 81.127 | — | — | -230.106 ± 164.525 | -308.138 ± 230.671 |
| Change from baseline to Day 309 | — | — | — | — | — | — | -117.353 ± 34.739 | — | — | -215.726 ± 168.115 | -299.218 ± 232.143 |
| Change from baseline to Day 337 | — | — | — | — | — | — | -113.073 ± 84.006 | — | — | -198.440 ± 162.932 | -279.478 ± 231.897 |
| Change from baseline to Day 365 | — | — | — | — | — | — | -81.653 ± 81.061 | — | — | -170.126 ± 146.154 | -165.656 ± 88.637 |
Percent change from baseline for plasma Lp(a) by cohort and at scheduled time points during the treatment period were presented.
| percent change | Cohorts 1-5: Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohorts 6-9: Placebo | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent change from baseline to Day 2 | 8.407 ± 8.491 | -13.943 ± 11.951 | -1.094 ± 7.699 | 8.295 ± 13.665 | 1.415 ± 1.925 | -4.027 ± 9.484 | -13.633 ± 21.683 | -1.570 ± 10.443 | -2.088 ± 20.604 | -21.583 ± 17.410 | -15.998 ± 20.674 |
| Percent change from baseline to Day 4 | 11.483 ± 13.532 | -9.649 ± 12.452 | -6.487 ± 10.577 | 2.462 ± 12.152 | -17.185 ± 7.985 | -8.416 ± 5.613 | -14.608 ± 23.141 | -12.800 ± 8.339 | -13.391 ± 16.046 | -34.553 ± 16.231 | -30.307 ± 21.326 |
| Percent change from baseline to Day 7 | 0.684 ± 10.535 | -17.968 ± 15.135 | -30.135 ± 14.583 | -34.017 ± 13.052 | -34.398 ± 4.843 | -46.725 ± 15.401 | -7.196 ± 21.378 | -29.518 ± 15.778 | -30.979 ± 14.986 | -58.222 ± 13.332 | -53.069 ± 12.226 |
| Percent change from baseline to Day 15 | -1.586 ± 13.188 | -46.805 ± 17.609 | -61.995 ± 9.342 | -65.000 ± 15.685 | -72.512 ± 5.451 | -69.051 ± 15.864 | -8.425 ± 12.997 | -53.145 ± 15.700 | -66.742 ± 7.852 | -82.712 ± 7.795 | -81.166 ± 5.437 |
| Percent change from baseline to Day 18 | -5.992 ± 12.779 | -56.826 ± 15.047 | -69.643 ± 6.846 | -76.332 ± 12.228 | -81.178 ± 6.122 | -84.107 ± 3.792 | — | — | — | — | — |
| Percent change from baseline to Day 22 | -3.064 ± 11.850 | -62.268 ± 12.534 | -77.121 ± 9.413 | -79.157 ± 11.601 | -87.780 ± 2.887 | -87.062 ± 2.254 | — | — | — | — | — |
| Percent change from baseline to Day 29 | -1.630 ± 11.948 | -65.771 ± 14.454 | -85.794 ± 7.534 | -85.001 ± 8.595 | -92.577 ± 1.368 | -92.124 ± 3.106 | -14.805 ± 19.160 | -72.210 ± 15.684 | -85.371 ± 7.046 | -95.448 ± 2.665 | -95.872 ± 1.879 |
| Percent change from baseline to Day 43 | -6.503 ± 11.507 | -72.060 ± 12.238 | -88.761 ± 7.479 | -88.558 ± 6.473 | -95.843 ± 1.293 | -96.365 ± 2.122 | -12.075 ± 21.690 | -75.430 ± 14.252 | -89.637 ± 5.632 | -98.226 ± 0.645 | -98.499 ± 0.676 |
| Percent change from baseline to Day 57 | 1.259 ± 10.313 | -70.163 ± 17.697 | -87.421 ± 9.001 | -88.472 ± 6.147 | -96.014 ± 2.073 | -96.685 ± 1.316 | -4.878 ± 25.711 | -76.174 ± 13.755 | -91.230 ± 6.742 | -98.547 ± 0.677 | -98.956 ± 0.400 |
| Percent change from baseline to Day 71 | -1.546 ± 12.389 | -67.809 ± 13.524 | -89.962 ± 4.968 | -86.866 ± 5.779 | -95.383 ± 2.145 | -96.332 ± 1.963 | — | — | — | — | — |
| Percent change from baseline to Day 85 | 1.275 ± 11.569 | -59.413 ± 12.808 | -88.913 ± 4.425 | -83.628 ± 8.427 | -94.747 ± 3.108 | -95.517 ± 2.334 | -7.875 ± 20.770 | -70.536 ± 15.558 | -87.328 ± 7.434 | -98.275 ± 0.948 | -98.814 ± 0.608 |
| Percent change from baseline to Day 113 | 3.430 ± 7.307 | -49.873 ± 16.496 | -82.051 ± 7.297 | -79.916 ± 11.140 | -91.351 ± 6.866 | -93.926 ± 2.891 | -6.786 ± 24.282 | -61.542 ± 17.396 | -80.484 ± 11.668 | -96.381 ± 3.343 | -97.963 ± 1.142 |
| Percent change from baseline to Day 155 | -15.206 ± 14.391 | — | — | -56.571 ± 13.156 | -86.424 ± 11.607 | -88.415 ± 3.561 | -7.233 ± 28.936 | -50.331 ± 20.523 | -68.537 ± 15.584 | -89.181 ± 10.167 | -95.757 ± 4.528 |
| Percent change from baseline to Day 183 | -22.300 ± 6.289 | — | — | — | -76.956 ± 26.029 | -85.437 ± 4.356 | -7.884 ± 23.516 | -41.792 ± 16.749 | -60.178 ± 18.037 | -85.355 ± 11.214 | -93.357 ± 5.554 |
| Percent change from baseline to Day 225 | -4.934 ± 17.577 | — | — | -84.342 ± NA | -73.464 ± 29.532 | -81.880 ± 11.062 | -4.730 ± 23.419 | -32.228 ± 14.640 | -51.725 ± 20.701 | -73.722 ± 17.160 | -86.702 ± 12.646 |
| Percent change from baseline to Day 253 | — | — | — | — | — | — | -24.858 ± 11.199 | — | — | -76.579 ± 15.153 | -80.199 ± 18.262 |
| Percent change from baseline to Day 281 | — | — | — | — | — | — | -23.787 ± 22.538 | — | — | -64.718 ± 19.802 | -75.169 ± 20.243 |
| Percent change from baseline to Day 309 | — | — | — | — | — | — | -31.515 ± 2.142 | — | — | -59.631 ± 21.986 | -72.336 ± 19.971 |
| Percent change from baseline to Day 337 | — | — | — | — | — | — | -26.688 ± 15.875 | — | — | -52.066 ± 26.070 | -66.022 ± 23.528 |
| Percent change from baseline to Day 365 | — | — | — | — | — | — | -19.333 ± 15.319 | — | — | -46.309 ± 23.019 | -56.484 ± 19.999 |
Collected over For all-cause mortality, from randomization until the end of trial completion; median (min, max) time on trial was 8.57 (0.26, 23.95) months. For AE, from first dose of trial drug until the end of trial; median (min, max) duration was 8.54 (0.23, 23.92) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohorts 1-5: Placebo | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Cohorts 6-9: Placebo | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| Cohort 1: Olpasiran 3 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 2: Olpasiran 9 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 3: Olpasiran 30 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 4 Olpasiran: 75 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cohort 5 Olpasiran: 225 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Cohort 6: Olpasiran 9 mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Cohort 7: Olpasiran 75 mg | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Cohort 8: Olpasiran 225 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Cohort 9: Olpasiran 675 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Cohorts 1-5: Placebo | Cohorts 6-9: Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/10 | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 0/5 | 0/6 |
| Cardiac telemetry abnormalInvestigations | 0/10 | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 0/5 | 0/6 |
| Event | Cohorts 1-5: Placebo | Cohorts 6-9: Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 2/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 1/10 | 1/10 | 2/6 | 0/6 | 2/6 | 0/6 | 0/6 | 2/9 | 0/9 | 0/5 | 0/6 |
| HeadacheNervous system disorders | 1/10 | 3/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/9 | 2/9 | 0/5 | 0/6 |
| Abdominal discomfortGastrointestinal disorders | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
| Injection site haemorrhageGeneral disorders | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
| Injection site painGeneral disorders | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 1/6 |
| COVID-19Infections and infestations | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
| CystitisInfections and infestations | 0/10 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
| GastroenteritisInfections and infestations | 0/10 | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
| SinusitisInfections and infestations | 0/10 | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/9 | 0/9 | 1/5 | 0/6 |
The safety analysis set consisted of all participants who received at least 1 dose of Olpasiran or placebo.
| Age, Continuous(years) | Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.0 ± 8.8 | 42.7 ± 16.0 | 50.2 ± 7.6 | 34.5 ± 11.5 | 51.5 ± 13.4 | 40.8 ± 14.3 | 52.7 ± 10.8 | 52.8 ± 8.3 | 58.2 ± 4.3 | 47.7 ± 13.1 | 49.2 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 3 | 2 | 1 | 3 | 0 | 3 | 3 | 4 | 1 | 29 |
| Male | 11 | 3 | 4 | 5 | 3 | 6 | 6 | 6 | 1 | 5 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 6 | 4 | 1 | 2 | 2 | 3 | 0 | 0 | 32 |
| Not Hispanic or Latino | 12 | 0 | 0 | 2 | 5 | 4 | 7 | 6 | 5 | 6 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Cohort 1: Olpasiran 3 mg | Cohort 2: Olpasiran 9 mg | Cohort 3: Olpasiran 30 mg | Cohort 4 Olpasiran: 75 mg | Cohort 5 Olpasiran: 225 mg | Cohort 6: Olpasiran 9 mg | Cohort 7: Olpasiran 75 mg | Cohort 8: Olpasiran 225 mg | Cohort 9: Olpasiran 675 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 0 | 1 | 3 | 1 | 1 | 0 | 0 | 1 | 14 |
| White | 16 | 2 | 6 | 5 | 3 | 5 | 7 | 9 | 5 | 5 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2018 to primary completion in Apr 2023, 56 months.
Results were first posted in Jan 2026, 2 years 9 months after primary completion.
Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 56 months is above that.
Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olpasiran